Navigation Links
UK survey shows differences between clinicians treating rheumatology in pregnancy

This study, which is one of the first of its kind, collated responses from rheumatologists (52% consultants) and obstetricians (94% consultants) on the subject of patient education on safe treatments for use during pregnancy, the existence of local guidelines on treating this patient population, and recorded HCP use of several individual drugs used during the pre-conception, pregnancy and breastfeeding period.

The survey results outlined variations around the use of non-steroidal anti-inflammatory medications (NSAIDs) with 32% of rheumatologists and 18% of obstetricians opting to continue treatment whilst 67% of rheumatologists and 39% of obstetricians opted to discontinue these treatments during pregnancy.

"The results of our study have shown that there are several different approaches to treating women of a childbearing age with rheumatic conditions. Whilst healthcare practitioners are aware that they should consult a specialist when unsure of a treatment decision, best practice guidelines, developed with consensus between rheumatologists, obstetricians and specialist nurses would benefit healthcare practitioners in the UK and Europe greatly" said Dr Sonia Panchal, University Hospital of Leicester NHS Trust, UK.

Only 25% of rheumatologists and 6% of obstetricians had guidelines that were locally developed for the management of this patient population. The results of the survey also showed that there were several variations in approaches to prescribing specific treatments in the group:

  • The majority of rheumatologists (92%), but only half of obstetricians (54%) would discontinue anti-TNF treatment during pregnancy
  • 95% rheumatologists compared to 52% of obstetricians would discontinue rituximab

Regarding other treatments for rheumatic conditions, there was considerable variation in practice with regard to prescribing medications including sulphasalazine (Salazopyrin), azathioprine (Imuran / Azasan) and methotrexate (Rheumatrex).

The questionnaire was distributed to 1000 HCPs across the UK, via the British Society of Rheumatology and the British Maternal Foetal Medicine Society. Responses were received from 102 rheumatologists and 33 obstetricians and responses were analysed using online software.


Contact: Rory Berrie
European League Against Rheumatism

Related biology news :

1. USDA/AIA survey reports 2010/2011 winter honey bee losses
2. Willow cut-stem growers surveyed
3. Survey says: Genetics affect whether were willing to take surveys
4. Survey shows many are still clueless on how to save energy
5. First nearshore survey of Antarctic krill reveals high density, stable population in shallow waters
6. Scientific coral reef survey to be conducted in Bonaire
7. Study finds that simple 2-question survey can better identify hungry children
8. Stanford pollster to discuss latest survey on global warming
9. Survey reports latest honey bee losses
10. New survey techniques improve narwhal population estimates
11. US women and minority scientists discouraged from pursuing STEM careers, national survey shows
Post Your Comments:
(Date:6/2/2016)... 2016 The Department of Transport Management ... 44 million US Dollar project, for the , ... Personalization, Enrolment, and IT Infrastructure , to ... and implementation of Identity Management Solutions. Numerous renowned international vendors ... Decatur was selected for the most compliant and ...
(Date:5/24/2016)... patient care by providing unparalleled technology to leaders of the medical imaging industry.  As ... added to the range of products distributed by Ampronix. Photo - ... ... ... ...
(Date:5/9/2016)... Elevay is currently known as ... for high net worth professionals seeking travel for work ... world, there is still no substitute for a face-to-face ... your deal with a firm handshake. This is why ... of citizenship via investment programs like those offered by ...
Breaking Biology News(10 mins):
(Date:6/23/2016)... 23, 2016   Boston Biomedical , an ... designed to target cancer stemness pathways, announced that ... Orphan Drug Designation from the U.S. Food and ... cancer, including gastroesophageal junction (GEJ) cancer. Napabucasin is ... inhibit cancer stemness pathways by targeting STAT3, and ...
(Date:6/23/2016)... Calif. , June 23, 2016  The Prostate Cancer Foundation ... increasingly precise treatments and faster cures for prostate cancer. Members of the Class ... across 15 countries. Read More About the Class of ... ... ...
(Date:6/23/2016)... ... June 23, 2016 , ... In a new case report published ... how a patient who developed lymphedema after being treated for breast cancer benefitted from ... the paradigm for dealing with this debilitating, frequent side effect of cancer treatment. ...
(Date:6/23/2016)... ... June 23, 2016 , ... ClinCapture, the only ... Center and will showcase its product’s latest features from June 26 to June ... scientific poster on Disrupting Clinical Trials in The Cloud during the conference. ...
Breaking Biology Technology: